May 15, 2013
Relypsa Announces Appointment of John Orwin as Chief Executive Officer
May 13, 2013
Relypsa Completes Patient Enrollment in Pivotal Phase 3 Program for the Treatment of Hyperkalemia
February 20, 2013
Relypsa Enrolls Initial Patient in Pivotal Phase 3 Program for the Treatment of Hyperkalemia
January 02, 2013
Relypsa Announces Agreement with FDA on Special Protocol Assessment for Patiromer Phase 3 Trial for the Treatment of Hyperkalemia
January 02, 2013
Relypsa Announces Changes to Board of Directors
December 10, 2012
Kristine M. Ball Joins Relypsa as Senior Vice President, Chief Financial Officer
August 15, 2012
Relypsa Announces $80 Million Private Financing Transaction
February 08, 2012
Lance Berman, M.D. Joins Relypsa as Senior Vice President, Commercial Strategy & Medical Affairs
October 25, 2011
Wilhelm Stahl, Ph.D. Joins Relypsa as Senior Vice President, Pharmaceutical Operation
June 28 , 2011
Relypsa Begins Treatment in AMETHYST-DN Trial of RLY5016 for Hyperkalemia in Diabetic Nephropathy Patients with Chronic Kidney Disease
May 23, 2011
Relypsa Announces Presentation of Positive Phase 2 Results for RLY5016 at American Society of Hypertension Meeting
May 19, 2011
Relypsa Adds Key Leadership Positions to Support Late-Stage Development and Pre-Launch Commercial Activities
September 15, 2010
Positive Phase 2 Data for RLY5016 Presented in Late-Breaker Session at Heart Failure Society of America Meeting
September 13, 2010
Relypsa Raises $70 Million in Series B - Financing; Funds to Support Late-Stage Development of RLY5016 - New Board Members Announced
August 29, 2010
ESC 2010: Hot Line I: New oral potassium binder lowers potassium levels in patients with heart failure and heart failure with chronic kidney disease
June 16, 2010
Relypsa Initiates Open-Label Phase 2 Clinical Study of RLY5016 for the Management of Hyperkalemia
June 16, 2010
Relypsa Appoints Claire J. Lockey Vice President, Regulatory Affairs
October 7, 2009
Relypsa Initiates Phase 2b Clinical Trial of RLY5016 for the Prevention of Hyperkalemia in Heart Failure Patients
January 9, 2008
Relypsa appoints Ronald A. Krasnow Senior Vice President, Intellectual Property and Chief Patent Counsel
October 29, 2007
Relypsa formed with $33 Million Series A Funding to discover and develop polymeric drugs
|
